Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $0.5
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Tommie Reerink has maintained a Sell rating on Atara Biotherapeutics (NASDAQ:ATRA) and reduced the price target from $3 to $0.5.
November 10, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has reaffirmed a Sell rating on Atara Biotherapeutics and significantly cut the price target from $3 to $0.5.
The reduction in price target by a major analyst like Goldman Sachs suggests a bearish outlook on the stock, which could lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100